SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending heavily as the community anticipates major clinical trial milestones and a potential short squeeze, with investors debating the company's valuation and the outcome of the ongoing REGAL trial. Bulls are pointing to high institutional interest and the potential for a buyout, while a vocal group of bears warns of high risk and potential dilution.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is seeing heightened activity as investors weigh its deep valuation and strong free cash flow against persistent concerns over broadband subscriber losses and intense competition from satellite internet. The community remains divided, with some betting on a rebound driven by theme park growth, sports broadcasting, and dividend reliability, while others express frustration over the stock's long-term stagnant price performance.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market interest as investors react to the potential win of a major Japanese government J-LEO contract and the company's competitive positioning against Starlink. The community is actively discussing a possible short squeeze and the strategic implications of partnerships as they monitor institutional positioning and upcoming launch milestones.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential inclusion in the Russell 1000 index, driving significant options activity and ongoing conflict between bullish sentiment and short sellers. The community is actively discussing the stock's high trading volume and the potential for a gamma squeeze, while remaining hyper-focused on upcoming regulatory catalysts and global expansion plans.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is capturing significant market attention following the FDA approval of Lumvoa for thyroid eye disease, with the community actively debating the drug's commercial potential against established competitors like Tepezza. Discussion is heavily focused on the company's immediate launch strategy, the significance of the broad label covering both active and chronic disease, and whether current valuation levels account for this pivotal commercial milestone.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is seeing heightened activity as community members debate its aggressive share buyback strategy, institutional ownership levels, and a potential partnership with SpaceX to enhance mobile offerings. While some investors view the stock's significant decline as an undervalued entry point, others remain skeptical, focusing on the company's substantial debt load and stiff competition from satellite internet providers.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is drawing significant attention from traders speculating on potential short squeezes and recurring volatility, with many community members debating whether to hold through price swings or treat it as a pump-and-dump opportunity. Discussions are heavily focused on technical setups, volume spikes, and comparisons to previous price runs, while some users express frustration over communication lapses and market suppression.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidia Corp is trending as investors aggressively position ahead of a critical patent litigation ruling, with strong bullish sentiment fueled by robust adoption metrics for its Yutrepia product. Community discussion remains heavily focused on the stock's massive long-term outperformance compared to peers and speculation that a favorable court decision could trigger significant upside or an acquisition.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing significant volatility as investors digest reports of U.S. military strikes in the Middle East and a potential Iran peace deal. The community is actively debating the reliability of geopolitical headlines while navigating heavy price swings driven by institutional positioning and broader tech sector uncertainty.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors debate its valuation, specifically questioning whether it should be viewed as a traditional social media platform or a high-growth data infrastructure play for AI training. Community sentiment is deeply divided, with traders focused on structural support levels and potential short-term volatility, while others speculate on long-term monetization potential through data licensing deals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ZNTL
Share Price: $3.96

Contract Selected: Dec 18, 2026 $5 Calls

Buy Zone: $1.23 – $1.52
Target Zone: $2.22 – $2.72
Potential Upside: 70% ROI

Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

Every trade is a home run. Over 96% win rate on all trades for the past two years, over 1,000,000+ total trades. Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial advice. Trading involves risk, and past performance is not indicative of future results.

Fxcapta

fxcapta.com

StockTwits Web

Zentalis Pharmaceuticals Inc


Share Price: $3.96

Contract Selected: Dec 18, 2026 $5 Calls

Buy Zone: $1.23 – $1.52
Target Zone: $2.22 – $2.72
Potential Upside: 70% ROI

Time to Expiration: 205 Days | Updates via 